Our first cell therapy treatments are built on CAR T (chimeric antigen receptor T cell) technology, which uses genetically modified immune cells to target cancer cells. In 2017, we were acquired by Gilead Sciences, Inc., and this partnership has rapidly accelerated the advancement of our pipeline, including the launch of our first cell therapy, Yescarta® or Axi-Cel™ (axicabtagene cilo¬leucel), a CAR T therapy to treat certain types of relapsed or refractory non-Hodgkin lymphoma.
Together with Gilead, we have acquired additional technologies to support the development of next-generation cell therapies.
For further information on Kite Pharma EU as a potential new employer and on our career opportunities, you can reach us at +31 (0)20 237 43 91 or via firstname.lastname@example.org
© 2023 Copyright – Kite Pharma.